Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 4/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 2/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11759686 | 0.89 | CES1 (0.47) | CES1HTR2AHRH1RETNOS3 | |
| SCHEMBL11755014 | 0.78 | CYP3A4 (0.50) | CES1HTR2AHRH1RETL3MBTL1 | |
| SCHEMBL11759087 | 0.78 | HRH1 (0.50) | CES1HTR2AHRH1RETCYP1A2 | |
| SCHEMBL11757310 | 0.78 | CES1 (0.47) | CES1RETNOS3TDP1L3MBTL1 | |
| SCHEMBL11761027 | 0.77 | MAOB (0.37) | CES1HTR2AHRH1TDP1L3MBTL1 | |
| SCHEMBL11761032 | 0.77 | MAOB (0.37) | CES1HTR2AHRH1TDP1L3MBTL1 | |
| SCHEMBL11755375 | 0.76 | SLC6A2 (0.41) | CES1HTR2AHRH1RETCYP1A2 | |
| SCHEMBL11757881 | 0.76 | LMNA (0.38) | CES1HTR2AHRH1RETCYP1A2 | |
| SCHEMBL11757306 | 0.76 | BCHE (0.37) | CES1HTR2ARETHTTSMN1; SMN2 | |
| SCHEMBL11757303 | 0.76 | BCHE (0.37) | CES1HTR2ARETHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210030695-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030695-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | CES1 3013/4885HTR2A 2257/4885HRH1 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.